Tuesday, May 08, 2018 9:19:05 AM
ADR is 3:1 - NICE!
60 percent upside
Added 36.83 US stock
Added 29.38 US cash
Not a bad deal!
Never Never buy/sell any security based on my post(s). I DO NOT receive any compensation in any form (cash or shares) from any company or 3rd party mentioned in my post(s). All my posts are my OPINION only.
ALWAYS CHECK WITH A FINANCIAL ADVISER
Recent TAK News
- Takeda annonce ses résultats pour l’exercice 2023 et ses perspectives pour l’exercice 2024, confirmant son engagement en faveur du développement d’un portefeuille de produits à un stade avancé et de l’augmentation de la marge bénéficiaire... • Business Wire • 05/10/2024 11:03:00 AM
- Takeda veröffentlicht Ergebnisse für das Geschäftsjahr 2023, liefert Ausblick auf das GJ 2024, und bekräftigt Bekenntnis zur Pipeline-Entwicklung in der späten Entwicklungsphase sowie zur Steigerung der operativen Gewinnmarge • Business Wire • 05/09/2024 09:07:00 PM
- Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion • Business Wire • 05/09/2024 06:07:00 AM
- 2023年度通期業績および2024年度の見通しを公表 - 後期段階のパイプライン開発とCore営業利益率改善へのコミットメントを強調 • Business Wire • 05/09/2024 06:07:00 AM
- HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda • GlobeNewswire Inc. • 04/26/2024 12:30:00 PM
- Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer • Business Wire • 04/26/2024 12:30:00 PM
- Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder • PR Newswire (US) • 04/23/2024 11:00:00 AM
- Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs • PR Newswire (US) • 04/22/2024 08:10:00 AM
- U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease • Business Wire • 04/18/2024 11:00:00 PM
- Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food • Business Wire • 04/08/2024 12:00:00 PM
- Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE • PR Newswire (US) • 03/27/2024 12:56:00 PM
- Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE • PR Newswire (US) • 03/27/2024 12:53:00 PM
- Takeda annonce les candidats au conseil d’administration pour la prochaine assemblée générale des actionnaires • Business Wire • 03/27/2024 05:01:00 AM
- Takeda gibt Kandidaten für den Vorstand bei der kommenden Aktionärsversammlung bekannt • Business Wire • 03/27/2024 05:01:00 AM
- Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting • Business Wire • 03/26/2024 11:07:00 PM
- 第148回定時株主総会に提案する取締役候補者について • Business Wire • 03/26/2024 11:07:00 PM
- Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) • Business Wire • 03/26/2024 12:00:00 PM
- 武田薬品、Ph+ ALLの初発成人患者に対するアイクルシグ®(ポナチニブ)の医薬品承認事項変更申請(sNDA)について、FDAからの承認取得を発表 • Business Wire • 03/21/2024 01:39:00 PM
- Takeda meldet sNDA-Zulassung von ICLUSIG® (Ponatinib) durch die FDA bei erwachsenen Patienten mit neu diagnostizierter Ph+ ALL • Business Wire • 03/21/2024 07:33:00 AM
- Takeda annonce l'approbation par la FDA des États-Unis d'une demande supplémentaire de nouveau médicament (sNDA) pour ICLUSIG ® (ponatinib) chez les patients adultes atteints de leucémie lymphoblastique aiguë (LAL Ph+) nouvellement diagnostiquée • Business Wire • 03/20/2024 07:18:00 PM
- Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL • Business Wire • 03/19/2024 04:20:00 PM
- CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders • GlobeNewswire Inc. • 03/19/2024 10:30:54 AM
- Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia • Business Wire • 03/13/2024 12:00:00 PM
- 武田薬品とBiological E. Limited、デング熱流行地域におけるワクチンへのアクセス促進で協力 • Business Wire • 02/28/2024 12:03:00 PM
- Takeda et Biological E. Limited s’associent pour accélérer l’accès au vaccin contre la dengue dans les zones endémiques • Business Wire • 02/27/2024 10:26:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM